FibroGen shares take a beating as CEO reveals safety data manipulation for its blockbuster contender roxadustat
FibroGen $FGEN backtracked on some of the key safety data used to boost hopes for their anemia drug roxadustat, eliminating its claim of superiority over …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.